Madrigal Pharmaceuticals (NASDAQ: MDGL)
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-12-20 | ||||||
REV |
FY 2023 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2023-11-09 | ||||||
REV |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Madrigal Pharmaceuticals (NASDAQ: MDGL) through any online brokerage.
Other companies in Madrigal Pharmaceuticals’s space includes: Valneva (NASDAQ:VALN), Chinook Therapeutics (NASDAQ:KDNY), Syndax Pharmaceuticals (NASDAQ:SNDX), FibroGen (NASDAQ:FGEN) and CareDx (NASDAQ:CDNA).
The latest price target for Madrigal Pharmaceuticals (NASDAQ: MDGL) was reported by Cantor Fitzgerald on Friday, August 12, 2022. The analyst firm set a price target for 4.00 expecting MDGL to fall to within 12 months (a possible -94.55% downside). 50 analyst firms have reported ratings in the last year.
The stock price for Madrigal Pharmaceuticals (NASDAQ: MDGL) is $73.34 last updated August 12, 2022, 8:00 PM UTC.
The next Madrigal Pharmaceuticals (MDGL) dividend date is projected to be Thursday, September 1, 2022.
Madrigal Pharmaceuticals’s FY earnings are confirmed for Wednesday, December 20, 2023.
There is no upcoming split for Madrigal Pharmaceuticals.
Madrigal Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.